BattellePharma Signs Second Development Agreement With Eiffel Technologies for Asthma Therapy; Two Companies Collaborate On Asthma Therapy.Business Editors & Health/Medical Writers BIOWIRE2K COLUMBUS, Ohio--(BW HealthWire)--June 13, 2002 BattellePharma today announced it has signed a second agreement with Eiffel Technologies. Under this contract, Eiffel will create drug nanoparticles using its suite of Supercritical Fluid A supercritical fluid is any substance at a temperature and pressure above its thermodynamic critical point. It has the unique ability to diffuse through solids like a gas, and dissolve materials like a liquid. (SCF SCF Service Canadien des Forêts (Canadian Forest Service) SCF Stem Cell Factor SCF Scientific Committee on Food (European Commission) SCF Service Canadien de la Faune ) technologies for BattellePharma's asthma product, now in development. BattellePharma plans to exploit the benefits of nanoparticles, which include enhanced suspension stability. The reformulation will be tested with BattellePharma's Mystic(TM) inhalation delivery technology. Each company will retain the intellectual property that relates to its technology. Specific details of the agreement and project were not disclosed. BattellePharma's Mystic electrohydrodynamic inhalation technology addresses the limitations other inhalers experience, including inconsistent dosing and poor delivery efficiencies. Existing devices, such as metered dose and dry powder inhalers The Dry Powder Inhaler is generally a proprietary device to deliver medications for the treatment or maintenance management of respiratory diseases and conditions. These conditions or diseases may include Asthma, Bronchitis, Emphysema, COPD and Diabetes. , often require patients to produce specific coordinated and difficult breathing patterns, which limit the effectiveness of the devices. In a recent clinical trial, the Mystic device achieved 80 percent delivery of the drug to the lung versus 20 percent in a competitive marketed inhaler inhaler /in·hal·er/ (in-hal´er) 1. an apparatus for administering vapor or volatilized medications by inhalation. 2. ventilator (2). in·hal·er n. . "We are pleased to continue our relationship with Eiffel," said Dennis Cearlock, BattellePharma's CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "Our Mystic technology, which outperforms current inhaled in·hale v. in·haled, in·hal·ing, in·hales v.tr. 1. To draw (air or smoke, for example) into the lungs by breathing; inspire. 2. drug delivery options, allows for highly reproducible dosing, resulting in better disease management and lower overall doses for improved safety. We believe the combination of the SCF technology and our Mystic delivery system will enhance the performance of BattellePharma's asthma product." "Eiffel reformulates new, currently marketed, and generic pharmaceuticals to improve the performance of therapies and offer more convenient, patient-friendly delivery of drugs," said Christine Cussen, Eiffel Technologies CEO. "This second agreement represents the potential for Eiffel to progress towards a long term supply agreement with a highly reputable, emerging pharmaceutical company." Eiffel Technologies Ltd. is a bioengineering bioengineering Application of engineering principles and equipment to biology and medicine. It includes the development and fabrication of life-support systems for underwater and space exploration, devices for medical treatment (see company focused on improving the performance and delivery of pharmaceuticals, proteins and peptides. Based in Melbourne, Australia, the company is dedicated to the development and commercialization of SCF drug re-engineering technologies to improve therapeutic outcomes and patient administration of new and currently marketed pharmaceuticals. For more information on Eiffel Technologies, see the company website www.eiffeltechnologies.com.au for details. BattellePharma is a pre-public specialty pharmaceutical company leveraging science and technology to design more effective medicines. The company has a growing portfolio of nine products in development, with several in early clinical trials. The products are based on three proprietary platforms: Mystic(TM) inhalation technology, novel formulation technologies, and inhaled anticancer therapy. The company develops products by combining these platforms with novel or generic compounds to create therapies to treat respiratory and systemic diseases and lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. . BattellePharma has partnerships with numerous pharmaceutical corporations, including Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a diversified pharmaceuticals and health care company. It has over 65,000 employees and operates in 130 countries. The corporate headquarters are in Abbott Park, Illinois, a neighborhood of North Chicago, Illinois. , GlaxoSmithKline, Pfizer Inc., Viasys Healthcare, and ViroPharma Inc., and is a subsidiary of Battelle Memorial Institute The Battelle Memorial Institute is a private not-for-profit applied science and technology development company headquartered in Columbus, Ohio. The institute opened in 1929 but traces its origins to the 1923 will of Ohio industrialist Gordon Battelle which provided for its , the world's largest independent and private research and development organization. For more information on BattellePharma, reference the company's website at www.battellepharma.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion